OTR3001 - An Open-Label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-Release Tablets in Opioid Experienced Children from Ages 6 to 16 Years Old, Inclusive, with Moderate to Severe Malignant and/or Nonmalignant Pain Re

Grants and Contracts Details

StatusFinished
Effective start/end date8/4/1110/31/14

Funding

  • Purdue Pharma LP: $35,516.00